Arcus Biosciences Inc . (NYSE:RCUS) stock has reached a 52-week low, touching down at $13.48. This latest price movement ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated ...

Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...

HAYWARD, Calif., January 24, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer. The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled ...

Arcus Biosciences (RCUS) announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer effective January 31, 2025. Dr.

Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business had revenue of $48.00 million for the quarter, compared to analysts’ expectations ...

Ruben Amorim suggested that Marcus Rashford is not putting maximum effort in every day and that kind of attitude simply would ...

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...